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Heart failure is a major health problem with an increasing incidence and prevalence of the
disease. The role of both established natriuretic peptides: B-type natriuretic peptide (BNP)
and N-terminal prohormone pro-brain natriuretic peptide (NT-proBNP) in acute and
chronic heart failure (HF) has been intensively studied. Its testing is routine in clinical
practice for diagnosis and prognosis in HF. However, increased clariﬁcation and under-
standing of the interplay in the pathophysiology of HF revealed several new potential
cardiac biomarkers. These novel biomarkers soluble ST2, galectin, copeptin and, mid-
regional fragment of pro-adrenomedullin (MR-proADM) may aid in the diagnostic and
prognostic evaluation of acute and chronic heart failure.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Heart failure (HF) represents an increasing problem world-
wide and has an advancing trend, predominantly in elderlych Society of Cardiology.
logy, Na Homolce Hospit
am.cz (D. Vondráková).patients. The prevalence rate in the general population is 0.4–
2.0% and rapidly increases with age [1]. At the age of 50, the
prevalence rate is about 1%, whilst at the age of 80 and above,
almost one out of 10 people will suffer from heart failure [2].Published by Elsevier Urban & Partner Sp.z o.o. All rights reserved.
al, Roentgenova 2, Prague 5 150 30, Czech Republic.
.
Table 1 – Properties of biomarkers.
1. Accurate, reproducible, standardized measurements
2. Reasonable cost, short setting time
3. Biomarkers provide information that is not available from
clinical assessment
4. Knowing the measured level to aid in medical decision
making
5. High sensitivity and speciﬁcity
Table 2 – Classiﬁcation of biomarkers.
Biomarkers in heart failure
Inﬂammation
 C-reactive protein
 Tumour necrosis factor
 Interleukins 1, 6 and 18
Oxidative stress
 Oxidized low-density lipoproteins
 Myeloperoxidase
 Urinary biopyrrins
 Urinary and plasma isoprostanes
 Plasma malondialdehyde
Hormones
 Norepinephrine
 Renin
 Angiotensin II.
 Aldosterone
 Copeptin
 Endothelin
Myocyte injury
 Troponins T and I
 Creatine kinase MB fraction
 Heart-type fatty-acid protein
 Myosin light-chain kinase I
Myocyte stress
 Brain natriuretic peptide
 N-terminal pro-brain natriuretic peptide
 Midregional fragment of proadrenomedullin
Matrix remodelling
 ST2
 Galectin
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45% of women will die within 5 years [3].
HF is the clinical syndrome, in which the heart fails to
pump blood at a rate commensurate with the requirements
of the metabolizing tissues or is able to do so only with an
elevated diastolic ﬁlling pressure. HF is often a clinically
silent process, with progressive cardiac remodelling that
eventually leads to symptomatic presentation late in the
course of disease progression.
Clinical assessment and management is the keystone of
patients with HF, but has its limitations. Physicians have
used additional tools to aid clinical assessment, which are
helpful in making an accurate and prompt diagnosis, and
effectively prognosticate, treat and better identify high-risk
subjects. Biomarkers are one such tool.
A biomarker is a characteristic that is objectively mea-
sured and evaluated as an indicator of normal biological
processes, pathogenic processes, or pharmacologic responses
to a therapeutic intervention. A biomarker should fulﬁl
certain criteria to be useful clinically [4] (Table 1).
In current guidelines for heart failure it is recommended
to test BNP or its precursor NT-proBNP. [5]. But measurement
of BNP and NT-proBNP has its own limitations. A variety of
clinical factors inﬂuence level of natriuretic peptides includ-
ing the age and sex of the individual [6,7,8], renal function
[9,10], body mass index [11], thyroid function [12] and anae-
mia [10]. In respect to these drawbacks, research and trials
are needed to ﬁnd convenient biomarkers suitable for clinical
practice. In the article below we discuss more novel cardiac
biomarkers in HF and their applications in clinical practice
(Table 2).
1.1. Biomarkers of inﬂammation
The presence of inﬂammatory processes in HF has been
veriﬁed [13]. Clinical studies revealed that many inﬂamma-
tory cytokines such as tumour necrosis factor alpha (TNF-α),
and at least three interleukins 1, 6 and 18 are elevated in HF.
These cytokines are produced by nucleated cells in the heart
[14]. Experimental studies have shown that each cytokine has
various effects on cardiac function [15,16].
IL-6, TNF- α and IL-18 activate intracellular signalling
pathways and have various effects on remodelling, hyper-
trophy and apoptosis in HF [16]. IL-6 binds to plasma
membrane receptor complexes containing the receptor chain
gp130. The IL-6-gp130 complex is known to activate two
major signalling pathways, and these play important roles
in cardiac development, hypertrophy, protection and remo-
delling in response to physiological and pathological stimuli.
It has been reported that elevated serum levels of IL-6cytokines and gp130 proteins are strong prognostic markers
for morbidity and mortality in patients with HF or after a
myocardial infarction [17,18]. Matsumoto et al. [16] described
that serum IL-6 and high-sensitivity C-reactive protein (hs-
CRP) concentrations were more elevated in acute cardiac
decompensation in patients with left ventricular (LV) systolic
dysfunction compared to patients with preserved LV ejection
fraction. Further, it has been reported that concentrations of
IL-6 are higher in patients with asymptomatic LV systolic
dysfunction compared to patients with normal LV function.
IL-6 negatively correlated with LV ejection fraction and the
diagnostic value of IL-6 (in this study) is able to predict the
progress of heart failure [19].
The effect of TNF-α on cardiomyocytes is mediated by two
types of TNF-α cell surface receptors, namely TNF receptor
(TNFR) 1 and TNFR 2. In HF activation, TNFR 1 has proapop-
totic effects—facilitated cardiac remodelling and apoptosis in
cardiomyocytes, while stimulation of TNFR 2 has an anti-
apoptotic effect [20]. The fragment of the extracellular part of
both receptors is possible to detect in blood as soluble forms,
sTNFR-1 and sTNFR-2, and their blood levels are elevated in
patients with severe HF [21]. These soluble cytokine receptors
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effect of TNF- α.
Rivera et al. [22] determined urinary levels of sTNFR-1 and
sTNFR-2 in patients with HF. This study showed that plasma
and urinary levels of TNF receptors were increased in
patients with higher NYHA classes. In clinical trials of severe
systolic dysfunction, elevated TNF- α and IL-6 were asso-
ciated with increased mortality [23].
Dunlay et al. [24] studied the level of TNF- α in patients
with both preserved and reduced ejection fraction (EF). The
results showed that elevated TNF-α is independently asso-
ciated with mortality in patients with heart failure regardless
of EF. This biomarker is suitable for risk prediction in all
categories of HF.
HF is linked with inﬂammatory response and hs-CRP as a
marker of inﬂammation modulates the disease process. CRP
is synthesized by the liver in response to numerous stimuli,
for example proinﬂammatory cytokine IL-6. CRP attenuates
nitric oxide production in endothelial cells, increases produc-
tion of endothelin-1 and the expression of endothelial adhe-
sion molecules [14,25]. These results show that CRP directly
negatively inﬂuences vascular endothelium. Multivariate
analysis indicated that an increased hs-CRP level is an
independent predictor of adverse outcomes in patients with
acute or chronic heart failure [26].
1.2. Oxidative stress
Oxidative stress is characterized by an imbalance between
the formation of reactive oxygen species (ROS) and endogen-
ous antioxidant mechanisms. Under physiological condi-
tions, low concentrations of ROS (including superoxide
anion, hydrogen peroxide and hydroxyl radical) have bene-
ﬁcial effects. ROS inﬂuence processes of cellular response to
infectious agents, participate in cell signalling and as a
stimulus of mitogenesis response [27,28]. Overproduction of
ROS may result in pathological consequences such as damage
to cell structures, including lipids, DNA and proteins.
Oxidative stress plays a role in the aetiology of cardiovas-
cular diseases such as atherosclerosis, ischaemic heart dis-
ease, hypertension and heart failure [27]. An obvious
mechanism through which myocardial oxidative stress might
impair cardiac function is oxidative damage to cellular
proteins and membranes, thereby inducing cellular dysfunc-
tion or death through apoptosis and necrosis. In the heart,
further effects of ROS can inﬂuence extracellular matrix
remodelling through the activation of the matrix metallopro-
teinases (MMPs) [29].
MMPs are a family of protease enzymes capable of degrad-
ing all the matrix components of the heart. ROS modulate
ﬁbroblast proliferation, collagen synthesis, activate MMPs
and also increase MMPs expression [29].
The superoxide anions contribute to vascular endothelial
dysfunction. Superoxide anions are a potent inactivator of
nitric oxide (NO), it results in the reduction of NO bioavail-
ability. Furthermore, the reaction between NO and super-
oxide generates peroxynitrite, which is itself a potent and
very reactive ROS [30].
Inﬂammatory cells, mitochondria, xanthine oxidase and
the family complex of enzymes termed NADPH oxidases aresources of ROS. Several factors which are involved in patho-
physiology of HF, such as angiotensin II, α-adrenergic ago-
nists, endothelin-1, tumour necrosis factor-α can stimulate
ROS production by NADPH oxidases [31]. In vitro studies
revealed a pivotal role of NADPH oxidase in angiotensin II-
induced cardiac hypertrophy and interstitial ﬁbrosis by using
gene-modiﬁed mice with defective NADPH oxidase activity
[32]. But it should be noted that ROS production by the higher
activity of an enzymatic source can modulate or trigger the
activity of other ROS sources (e.g., NADPH oxidase can drive
ROS production by NO synthase).
Direct markers of oxidative stress have not been fully
satisfactorily established and their measurement is difﬁcult.
In clinical practice we can determine indirect markers of
oxidative stress of heart failure, including plasma levels of
myeloperoxidase [33] and levels of isoprostane—speciﬁcally
8-iso-PGF2α evaluated in the pericardial ﬂuid [34]. The levels
of both markers correlate with the severity of heart failure. In
addition, with impaired hemodynamics in patients with HF
[35] and independently predict an adverse prognosis in
patients with moderate-to-severe heart failure [36]. Elevated
levels of uric acid are associated with increased xanthine
oxidase activity, which is a source of ROS. So uric acid is a
simple, useful, but nonspeciﬁc indicator of enhanced oxida-
tive stress. ROS in fact exert multiple effects in the patho-
physiology of HF and the elucidation of all these processes
should be helpful in the therapeutic approach. Statins appear
to have a “cardioprotective” role not only by their effect of
lowering cholesterol but also by improving NO-dependent
vasodilation through attenuation of endothelial superoxide
anion radical formation [37]. On the basis of this information
statin administration can decelerate pathological processes
conditioned by ROS.2. Hormones, copeptin
Copeptin is cosynthesized with vasopressin (AVP), also
known as antidiuretic hormone. Copeptin is a glycopeptide
consisting of 39 amino-acids. It is the C-terminal part of pro-
AVP, synthesized with AVP in the hypothalamus and released
from the neurohypophysis upon hemodynamic or osmotic
stimuli [38]. Physiologic functions of AVP are mediated
through different receptors (R) subtypes V1, V2, V3, oxytocin
receptor (OTR) and P2-purinergic receptor (P2R). V1 receptors
are found in vascular smooth muscle, cardiac myocytes and
cause vasoconstriction and a positive ionotropic effect. The
antidiuretic effect of vasopressin occurs via the activation of
V2R and the activation of V3R causes the secretion of
adrenocorticotropic hormone (ACTH) from the anterior
pituitary cells.
Oxytocin receptors (OTR) are nonselective vasopressin
receptors. The OTR has an equal afﬁnity for vasopressin
and oxytocin, whereas the V1R has a 30-fold higher afﬁnity
for vasopressin than for oxytocin [39]. OTR have been loca-
lized in many reproductive and nonreproductive tissues [40].
Importantly, OTR exist in a high density on vascular endothe-
lium and are responsible for vasodilatation mediated by
releasing nitric oxide. Whether vasopressin causes vasocon-
striction or vasodilatation depends on the vascular beds
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versus OTR) [41]. OTR are also in the heart and their activa-
tion stimulates the release of natriuretic peptide, which is
involved in natriuresis, regulation of blood pressure and cell
growth [42].
It has been shown that vasopressin exerts cardiac effects
also through the activation of P2Rs expressed on endothe-
lium. This animal in vitro study showed a negative ionotropic
effect and coronary vasoconstriction [43,39]. Inﬂuences of
V1R in the heart result in a positive ionotropic effect [44] so
studies of ionotropic effects of vasopressin and its effect on
coronary arteries are controversial. Clinical studies of low-
doses of vasopressin do not demonstrate adverse cardiac
effects of vasopressin [45]. It has been supposed that the
vasoconstrictor effect of vasopressin on coronary vessels, as
well as its effect on myocardium, may be dependent on
oxygen tension—which is signiﬁcantly attenuated during
hypoxia [46].
Recently reported studies have shown, that copeptin
levels predict outcomes in several medical conditions such
as acute exacerbation of chronic obstructive pulmonary
disease [47], ischaemic stroke [48] and even predict neurolo-
gical outcomes and mortality in cardiac arrest survivors [49].
Vasopressin concentrations are increased in patients with
heart failure [50]. Vasopressin is involved in the adverse
cardiac remodelling by acting V1R. Stimulation of this recep-
tor leads to increased myocyte contractile protein synthesis,
development of myocardial hypertrophy [51] and then sti-
mulates cardiac ﬁbroblast, resulting in increased myocardial
ﬁbrosis [52].
Stimulation of V1R in vascular smooth muscle increases
systemic vascular resistance, increasing impedance to ven-
tricular emptying (afterload) and thereby negatively affecting
ventricular function. Sustained increased afterload also
affects myocardial remodelling. Activation of V2R increases
water retention. Upregulation of these receptors results in an
increased movement of water from kidneys into the plasma,
which leads to increased water retention. This effect, if
sustained, may contribute to volume expansion that exacer-
bates diastolic wall stress, ventricular remodelling and dys-
function. V2R—mediated water reabsorption may participate
in hyponatremia, depending on the balance between regu-
lated water and sodium intake and excretion [53].
AVP has more limitations when determining its level in
plasma. More than 90% of vasopressin in the circulation is
bound to platelets and there is a possibility of underestimat-
ing the amount of AVP, since AVP is rapidly cleared from the
circulation (half-life 24 min). AVP is unstable in isolated
plasma, even when stored at −20 1C.
Copeptin has fewer limitations and is therefore an ideal
mirror reﬂecting AVP release [54,55]. In several studies
copeptin has been reported to be a useful biomarker, not
only in patients with chronic HF but also in patients with
post-acute myocardial infarction (MI).
Stoiser et al. [56] ﬁrst showed that copeptin is an excellent
predictor of outcome in advanced heart failure patients. Its
value is superior to that of BNP in predicting death and a
combined endpoint (death, re-hospitalization due to heart
failure), although BNP was still suitable for predicting chronic
heart failure (CHF) re-hospitalization.Nuehold et al. [57] reported that copeptin levels escalate
with NYHA. In patients with NYHA II and III, copeptin was
not only found to be the most potent single predictor of
mortality but was superior to BNP and NT-proBNP. For
patients with NYHA IV, copeptin provided independent
additional information, but was inferior to sodium levels
and especially glomerular ﬁltration.
In post-acute MI cases, copeptin was a signiﬁcant inde-
pendent predictor of death or heart failure compared to
event-free survivors. Copeptin levels were higher in STEMI
versus non-STEMI patients and in those with Killip class
above 1. Plasma copeptin correlated with NT-proBNP. In the
present study, 706 healthy volunteers were recruited from a
local HF screening study. Participants with a history of
cardiovascular disease were excluded from the study. Copep-
tin levels were signiﬁcantly higher in the male volunteers
compared with the females. In males, copeptin was corre-
lated with eGFR (estimated glomerular ﬁltration rate). In
females, the correlation of copeptin with eGFR was weak [58].
Kelly et al. [59] in a study with subjects with myocardial
infarction conﬁrmed the association between copeptin and
left ventricular ejection fraction, volumes, remodelling and
clinical heart failure post-acute MI.
Mason et al. [60] measured the plasma concentrations of
four stable precursor fragments of neurohormonal systems in
patients with chronic HF. 1237 patients with chronic and
stable HF were involved in the study. The following four
precursor fragments, mid-regional pro-atrial natriuretic pep-
tide (MR-proANP), mid-regional pro-adrenomedullin (MR-
proADM), C-terminal pro-endothelin-1 (CT-proET-1) and C-
terminal pro-vasopressin (CT-proAVP or copeptin), were
measured at randomization and after 3 months. It examined
the prognostic performance of these biomarkers which were
compared with the well-established B-type natriuretic pep-
tides (BNP and NT-proBNP). Measurement of stable precursor
fragments of vasoactive peptides provided prognostic infor-
mation independent of natriuretic peptides which are cur-
rently the best biomarkers for risk stratiﬁcation.
In summary, elevated plasma levels of AVP have been
associated with a poor prognosis in patients with chronic HF
and its measurement improves the prognostic evaluation of
these patients.
2.1. Myocyte stress, adrenomedullin
Adrenomedullin (AM) is a potent vasoactive peptide, origin-
ally isolated from human pheochromocytoma cells [61].
Subsequently AM has been discovered in many tissues
including adrenal medulla, brain, lung, kidney, gastrointest-
inal organs, or heart—cardiomyocyte, ﬁbroblasts and its
mRNA are highly expressed in endothelial cells [62,63].
AM is a member of the calcitonin gene-related peptide
(CGRP) superfamily, which includes calcitonin, calcitonin-
gene related peptides α and β (CGRP α, CGRP β), amylin and
intermedin, called adrenomedullin 2. This group of peptide
hormones is necessary for haemostasis in diverse tissues
[64]. The adrenomedullin gene is located on human chromo-
some 11, encoding a 185-amino acid pre-pro-hormone, pre-
pro-adrenomedullin. Following the cleavage of the 21-residue
N-terminal signal peptide, a 164-aminoacid pro-AM peptide is
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cally active peptides: AM and proAM N-terminal 20 peptide
(PAMP) [65]. PAMP evokes hypotension by inhibiting periph-
eral sympathetic nerve activity and reduces sympathetic tone
[66].
The mature molecule of AM is a 52-amino acid peptide. AM
possess many important physiological properties and mediates
its activities through binding to a complex receptor composed
of the calcitonin receptor like-receptor (CRLR) associated with
receptor activity modifying proteins RAMP-2 and RAMP-3.
RAMP isoforms determine the ligand selectivity [67].
AM has pleiotropic effects: vasodilatory, positive ionotro-
pic, antiapoptotic, suppresses the renin–angiotensin–aldos-
terone system, in kidney induces diuresis and natriuresis,
protects against oxidative stress as described by Ishimitsu
et al. [68]. Considerable evidence exists for the previously
described positive ionotropic effect of AM mediated by
increased intracellular cAMP [69]. Infusion of AM increases
cardiac output and reduces pulmonary wedge pressure with
little effect on heart rate and blood pressure, thereby result-
ing in increases in urine volume and natriuresis [70]. These
positive effects may be mediated by decreased afterload due
to peripheral vasodilatation and by the positive ionotropic
effect.
Adrenomedullin has been found to be increased in
patients with essential hypertension, renal failure, cardiac
hypertrophy [71], heart failure [72], acute myocardial infarc-
tion [73,74], sepsis [75] and community-acquired pneumonia
[76]. Plasma ADM concentration has a positive correlation
with circulating ADM and plasma creatinine levels [71]. These
pathological conditions increase production of AM and its
measurement should be useful in clinical practice.
The production of AM has been shown to be stimulated by
both cardiac pressure and overload.
Pousset et al. [72] assessed plasma adrenomedullin in
ambulatory patients (n¼117) with chronic heart failure and
found increasing plasma levels of AM with increasing NYHA
class. Immunoreactive AM plasma levels were similar in men
and women, did not correlate with age and were not inﬂu-
enced by the aetiology of heart failure (ischaemic vs. idio-
pathic aetiology). No correlation has been found between
ejection fraction and plasma levels of AM.
AM was an independent predictor of prognosis in predo-
minantly mild to moderate chronic HF.
Reliable quantiﬁcation of AM is impaired by the fact that
mature AM has a short plasma half-life of only ∼22 min [77],
creates a complex with complement factor H and is rapidly
cleared from the circulation.
In clinical practice, the more stable mid-regional fragment
of pro-adrenomedullin (MR-proADM) is determined, which
directly reﬂects the levels of the rapidly degraded active
peptide AM [78].
Klip et al. [79] evaluated the prognostic value of MR-
proADM in a subset of 214 patients with heart failure after
an acute MI from the OPTIMAAL study and compared this
with BNP and NT-proBNP. MR-proADM was a promising
biomarker and had a strong prognostic value for mortality
and morbidity in patients with HF after an acute MI. In this
study, MR-proADM had stronger predictive value than BNP
and NT-proBNP. Kahn et al. [74] assessed the prognosticimpact of MR-proADM after an acute MI and compared it
with NTproBNP.
The AM system is activated after MI and is a powerful
predictor of death and heart failure, especially in combina-
tion with an elevated NTproBNP giving additive prognostic
information.
In patients with chronic HF MR-proADM is an independent
predictor of mortality, which adds prognostic information to
NT-proBNP. In this study MR-proADM correlated with age,
creatinine and NYHA class, but not with LVEF. In contrast a
strong correlation was observed between NT-proBNP and
LVEF [80].
The prognostic value of MR-proADM for predicting 90-day
mortality in patients with acute heart failure was conﬁrmed
in the prospective trial BACH (Biomarkers in Acute Heart
Failure) [81]. Then Shah et al. [82] conﬁrmed the prognostic
value of MR-proADM in patients with acute heart failure.
In summary, measurement of MR-proADM provided a
reliable predictor of cardiovascular death and heart failure.
2.2. Matrix remodelling, ST2
Protein ST2 has a pluripotent role, and participates impor-
tantly in immunologic processes, as well as in the ﬁbrotic
heart response to injury. ST2 belongs to the interleukin-1 (IL-
1) receptor family [83]. The ST2 gene is located on human
chromosome 2 and is a part of the human IL-1 gene locus.
The ST2 gene encodes two isoforms of ST2 protein: trans-
membrane (ST2L) and soluble, circulating (sST2) isoforms
[84]. These different isoforms arise by alternative modiﬁca-
tions within the transcript of the ST2 gene [84].
Both sST2 and ST2L are induced in cardiomyocytes and
ﬁbroblasts by biomechanical stress [83]. sST2 is considered a
novel biomarker for cardiac strain.
ST2L is composed of three immunoglobulin (IgG) extra-
cellular domains, a transmembrane segment and an intra-
cellular domain that mediates intracellular signalling [84,85].
ST2L is responsible for positive feedback in immunologic
processes through activated type 2 T-helper cells (Th2) and
mast cells. ST2L is expressed by Th2 cells, but not expressed
by type 1 helper T cells [86].
The soluble isoform of ST2 lacks transmembrane and
cytoplasmatic domain and can be detected in serum [85].
Protein interleukin 33 (IL-33) is a functional ligand for ST2
[87].
The ﬁnding of IL-33 as a ligand for ST2 has clariﬁed the
role of IL-33/ST2 signalling in the myocardium. IL-33 is
induced by mechanical strain predominantly in cardiac
ﬁbroblasts.
IL-33 potently blocked cardiomyocyte hypertrophy
induced by either angiotensin II or phenylephrin [85]. The
sST2 protein abrogates the antihypertrophic effect of IL-33,
because it operates as a soluble decoy receptor by binding IL-
33 and in this way blocks preventive ST2L signalling. In
studies blocking the ST2L receptor by anti-ST2L monoclonal
antibodies has resulted in the blockage of the antihyper-
trophic effect of IL-33. Furthermore, targeted deletion of the
ST2 gene in mice (ST2-/-mice) enhanced cardiac hypertrophy
and ﬁbrosis following mechanical overload and impaired
contractility and survival, while administration of
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val in wild type mice, but not in ST2-/-mice. These data show
that IL33/ST2 signalling protects the myocardium under
mechanical overload. IL33/ST2 signalling is a cardioprotective
ﬁbroblast–cardiomyocyte paracrine system and soluble ST2
blocked the antihypertrophic effect of IL-33 [85].
Seki et al. [88] in an experiment with rat myocytes
revealed that IL-33 decreased caspase-3 activation—an
important step in the apoptotic cascade and increased
expression of the antiapoptotic gene Bcl-2. These antiapop-
totic effects were attenuated by sST2.
In clinical practice, measurements of sST2 in subjects with
HF should bring helpful insights into the biological process
that leads to adverse outcomes. sST2 concentrations are
positively associated with sex, age, systolic blood pressure
(more notably in men) and diabetes in individuals without
heart failure [89].
Januzzi et al. [90] evaluated a group of 593 patients
admitted to the emergency department with acute dyspnoea
with or without HF in the Pro-BNP Investigation of Dyspnoea
in the Emergency Department (PRIDE) study. The patients
were studied for one year. In this analysis, serum concentra-
tion of sST2 was higher in patients diagnosed with acute
destabilized HF, compared with those without cardiac causes
of dyspnoea. Higher concentrations of sST2 were associated
with a greater likelihood of HF diagnosis. Importantly, the
prognostic meaning of sST2 was considerable: concentrations
of the marker were higher in patients who were dead at 1
year compared with survivors [90]. There was a dose-
dependent relationship between sST2 concentrations and
risk of death at 1 year, and in multivariate regression analysis
for predictors of death at 1 year. An sST2 concentration
greater than 0.20 ng/ml strongly predicted 1-year mortality
in patients with and without HF.
In addition, the prognostic value of sST2 was additive to
that of NT-proBNP, in such a way that patients with eleva-
tions in both NT-proBNP and sST2 experienced the highest
rate of mortality in 1 year. Subjects with low values for both
markers had the best short-term prognosis. This signiﬁcation
between sST2 and NT-proBNP with prognosis holds for up to
4 years from presentation.
Rehman et al. [91] in a study of 346 patients with acute HF
from the PRIDE study examined the association between sST2
concentrations and clinical characteristics and prognosis.
sST2 value correlated with the severity of HF assessed by
NYHA, left ventricular ejection fraction, creatinine clearance,
B-type natriuretic peptide, amino terminal B-type natiuretic
peptide and C-reactive protein. ST2 was not associated with
previous HF, age, body mass index, atrial ﬁbrillation, or
aetiology of cardiomyopathy (ischaemic vs. nonischemic).
Shah et al. [92] described the relationship between sST2
levels and cardiac structure and function measured by
echocardiography in long-term mortality of 139 patients with
acute dyspnoea. Subjects had detailed 2-D echocardiography
at admission (median 45 hours after admission) with a
follow-up 4 years later. sST2 levels were associated with
higher LV-endsystolic area and volume, end-systolic dimen-
sion but not with left atrial dimension or volume.
sST2 was inversely related to LV ejection fraction and RV
fractional area change; sST2 was also associated with ahigher RV systolic pressure, more severe tricuspid regurgita-
tion, and a higher frequency of RV hypokinesis. sST2 was
negatively correlated with tissue Doppler E wave peak velo-
city but not with other traditional markers of diastolic
dysfunction. sST2 was higher in non-survivors at 4 years
versus survivors. sST2 also predicted death at 4 years inde-
pendently of other traditional clinical, biochemical and echo-
cardiographic markers of risk. This small study conﬁrmed an
association between sST2 and ventricular remodelling and
long-term mortality independent of other markers of risk.
In summary, products of the ST2 gene with ligand IL-33
modulate heart remodelling via effects on apoptosis, inﬂamma-
tion and ﬁbrosis. sST2 appears to be a biomarker for remodelling.
The circulating level of sST2 is correlated with short and long-
term post-discharge mortality in acute and chronic heart failure.
2.3. Matrix remodelling, galectin 3
Galectin 3 (Gal-3) is a member of the lectins family. Lectins are
proteins that speciﬁcally interact with carbohydrate sugars. The
interactions between lectins and their target carbohydrate sugars
occur via a carbohydrate recognition domain (CRD) within the
lectin. Galectins are a subfamily of lectins that have a CRD that
bind speciﬁcally to β-galactoside sugar molecules. CRDs typically
contain 130 amino acids. Currently 15 members of the galectins
family are known and, they can be divided into three subclasses,
those with one CRD (galectins 1, 2, 5, 7, 10, 11, 13, 14, and 15),
those with two CRDs (galectins 4, 6, 8, 9 and 12) and the third
subclass contains galectin-3. Galectin-3 has a unique chemical
structure for the lectin family with a non-lectin N-terminal
region (about 120 amino acids) connected to CRD [93]. Their
presence is necessary for the full biological activity of Gal-3,
which makes it able to bind with extracellular matrix proteins
and cell surface receptors [94].
Galectins can bind to cell surface—receptors and, antigens
and extracellular matrix glycans [93]. It seems that galectins
do not have speciﬁc individual receptors [95], but each can
bind to a set of cell surface or extracellular matrix glycopro-
teins containing suitable oligosaccharides. It has been shown
that galectins play important roles in multiple physiological
and pathological processes, including tumour development
and progression [96], immune and inﬂammatory responses
[97], neural degeneration, atherosclerosis, diabetes, and
wound repair as reviewed previously [93].
Galectin family members do not contain classical signal
sequences, however they can be secreted and thus belong to
the group of proteins that do not contain a signal sequence
but can function outside cells [98]. The secretion into extra-
cellular space can enable Gal-3 to interact with cell surface
receptors and antigens to trigger transmembrane signalling
cascades for different cellular functions. Expression of Gal-3
has been found in the cytoplasm and the nucleus of macro-
phages, eosinophils, neutrophils and mast cells [99].
In tissues, Gal-3 is plentifully detected in spleen, lung,
stomach, colon, adrenal gland, uterus and ovary. It is
expressed in heart, kidney, pancreas, liver, but in a lower
amount [100]. However a low expression level of Gal-3 can
change depending on the various pathophysiologic condi-
tions. If the disease progresses, gal-3 is signiﬁcantly up-
regulated. Cardiac remodelling is an essential feature of heart
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 4 5 – e 3 5 4 e351failure, and it is linked to disease progression. Recently, a role
for Gal-3 in cardiac remodelling and in the pathophysiology
of heart failure has been suggested. Fibrosis is a pivotal
process in maladaptive cardiac response. Fibroblasts and
macrophages are responsible for the initiation and progres-
sion of tissue ﬁbrosis [101,102].
The up-regulation of Gal-3 has been found in different
human pathological states, such as in liver cirrhosis [103],
idiopathic lung ﬁbrosis [104], chronic pancreatitis [105] and in
cardiac ﬁbrosis [106].
Fibroblast activation is deﬁned by increased expression of
cytoskeletal protein α smooth muscle actin (α-SMA—an
intracellular ﬁbrosis marker) and the extracellular type 1
collagen α-1 chain (COL1A1, an extracellular ﬁbrosis marker).
Both α-SMA and COL 1 A1 are up-regulated in ﬁbrotic tissue
via Gal-3-mediated activation. It affects the synthesis of new
matrix, and conversely inﬂuences degradation of extracellu-
lar matrix components by a set of tissue inhibitor metallo-
proteinases [107].
Gal-3 is positively associated with age and, body mass index,
negatively associated with eGFR and concentrations are higher
in women (14.3 ng/ml) compared with men (13.1 ng/ml) [108].
Sharma et al. [106] evaluated Gal-3 in rat and in human
subjects. This group studied homozygous Ren-2 rats that
exhibited overexpression of the murine Ren-2d renin gene,
resulting in severe hypertension with end-organ damage.
Myocardial biopsies obtained at an early stage of hypertrophy
before apparent HF showed that expression of Gal-3 was
increased speciﬁcally in the rats that later rapidly developed
HF. Gal-3 colocalized with activated myocardial macro-
phages. They found Gal-3-binding sites in rat cardiac ﬁbro-
blasts and the extracellular matrix. Furthermore, Sharma
et al. showed that infusion with Gal-3 in the pericardial sac
of normal, healthy rats led to the development of cardiac
remodelling with dysfunction and elevated expression of
collagens.
In human subjects, obtained biopsies from patients under-
going aortic valve replacement for aortic stenosis with pre-
served or depressed ejection fraction revealed that
myocardial Gal-3 expression was increased in aortic stenosis
patients with depressed ejection fraction [106].
Lok et al. [109] in the DEAL—Heart failure study, followed
232 patients with chronic heart failure (NYHA class III). Gal-3
was a signiﬁcant predictor of mortality risk after adjustment
for age and sex, and severity of HF and renal dysfunction, as
assessed by NT-proBNP and estimated glomerular ﬁltration
rate, respectively. The study found neither a signiﬁcant
correlation between Gal-3 levels and left ventricular ejection
fraction nor aetiology of HF.
In another study [110] of 599 patients with acute dys-
pnoea, an investigation of the utility assessment serum
biomarkers alone or together with natriuretic peptide for
diagnosis and short-term prognosis estimation in subjects
with acute HF was performed. The NT-proBNP was superior
to both apelin and Gal-3 for diagnosis of acute HF, although
Gal-3 levels were signiﬁcantly higher in subjects with HF
compared with those without HF. An elevated level of Gal-3
was the best independent predictor of 60-day mortality or the
combination of death/recurrent HF within 60 days. The
Kaplan–Meier analyses showed that the combination of anelevated Gal-3 with NT-proBNP was a better predictor of
mortality than either of the 2 markers alone.
Milting et al. measured plasma Gal-3 levels pre- and 30
days post-implantation of mechanical circulatory support
(MCSP) in 55 patients with end stage HF. Plasma BNP levels
were reduced by MCSP. Furthermore, patients who died had
signiﬁcantly higher plasma Gal-3 levels in comparison with
those patients who were successfully bridged to transplanta-
tion. Milting et al. [111] conﬁrmed the importance of Gal-3
level with disease progression.
In conclusion, Gal-3 is an independent marker for out-
come in HF and appears to be particularly useful in HF
patients with preserved LVEF [112].
Previous studies have examined the prognostic value of
Gal-3 in subjects with existing HF. Recently a study [108] has
been published, which reported the correlation of Gal-3 levels
with risk of new onset HF in apparently healthy subjects. The
conclusions are that higher circulating Gal-3 concentrations
are associated with a high risk of new onset HF and all-cause
mortality in the community.
We can summarize that Gal-3 appears to be a mediator of
cardiac ﬁbrosis, and is increased in acute and chronic heart
failure. Measurement of Gal-3 in patients with HF may
provide a novel clinical utility, because it reﬂects cardiac
remodelling and in conjunction with BNP or NT-proBNP it
could be used to better identify patients with a high risk of
readmission or death.
In addition, in the future we could perhaps use the
measurement of Gal-3 in asymptomatic subjects to identify
patients with early evidence of cardiac ﬁbrosis and apply
targeted therapy to delay the onset of HF.3. Conclusion
In this article we have discussed biomarker testing in patients
with heart failure. It is clear that the number of these biomarkers
has dramatically increased in the past several years. In addition,
various applications of biomarkers have been expanded, includ-
ing assessment diagnosis and prognostic evaluation. Using a
multimarker strategy could conﬁrm accurate risk stratiﬁcation of
patients with heart failure.
r e f e r e n c e s
[1] P.A. McKee, W.P Castelli, P.M. McNamara, et al., The natural
history of congestive heart failure: the Framingham study,
The New England Journal of Medicine 285 (1971) 1441–1446.
[2] H. Eriksson, Heart failure: a growing public health problem,
Journal of Internal Medicine 237 (1995) 135–141.
[3] D. Lloyd-Jones, R.J. Adams, T.M. Brown, et al., Heart disease
and stroke statistics-2010 update: a report from the
American Heart Association, Circulation 121 (2010) e46–e215.
[4] R.S. Vasan, Basic science for clinicians biomarkers of
cardiovascular disease molecular basis and practical
considerations, Circulation 113 (2006) 2335–2362.
[5] J.J.V. McMurray, S Adamopoulos, S.D. Anker, et al., ESC
Guidelines for the diagnosis and treatment of acute and
chronic heart failure 2012, European Heart Journal 33 (2012)
1787–1847.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 4 5 – e 3 5 4e352[6] M. Emdin, C. Passino, S. Del Ry, et al., Inﬂuence of gender on
circulating cardiac natriuretic hormones in patients with
heart failure, Clinical Chemistry and Laboratory Medicine 41
(2003) 686–692.
[7] A. Clerico, S. Del Ry, S. Maffei, et al., The circulating levels of
cardiac natriuretic hormones in healthy adults: effects of age
and sex, Clinical Chemistry and Laboratory Medicine 40
(2002) 371–377.
[8] I. Loke, B. Squire, J.E. Davies, et al., Reference ranges for
natriuretic peptides for diagnostic use are dependent on age,
gender and heart rate, European Journal of Heart Failure 5
(2003) 599–606.
[9] S. Anwaruddin, D.M. Lloyd-Jones, A. Baggish, et al., Renal
function, congestive heart failure, and amino-terminal pro-
brain natriuretic peptide measurement: results from the
ProBNP Investigation of Dyspnoea in the Emergency
Department (PRIDE) Study, Journal of the American College
of Cardiology 47 (2006) 91–97.
[10] I. Hogenhuis, A.A. Voors, T. Jaarsma, et al., Anaemia and
renal dysfunction are independently associated with BNP
and NT-proBNP levels in patients with heart failure,
European Journal f Heart Failure 9 (2007) 787–794.
[11] T.J. Wang, M.G. Larson, D. Levy, et al., Impact of Obesity on
Plasma Natriuretic Peptide Levels, Circulation 109 (2004)
594–600.
[12] M. Schultz, J. Faber, C. Kistorp, et al., N-terminal-pro-B-type
natriuretic peptide (NT-pro-BNP) in different thyroid
function states, Clinical Endocrinology 60 (2004) 54–59.
[13] G. Torre-Amione, Immune activation in chronic heart failure,
American Journal of Cardiology 95 (2005) 3–8.
[14] E. Braunwald, Biomarkers in heart failure, The New England
Journal of Medicine 358 (2008) 2148–2159.
[15] P Fischer, D. Hilﬁker-Kleiner, Survival pathways in
hypertrophy and heart failure: the gp130-STAT axis, Basic
Research in Cardiology 102 (2007) 393–411.
[16] M. Matsumoto, T. Tsujino, M. Lee-Kawabata, Serum
interleukin-6 and C-reactive protein are markedly elevated
in acute decompensated heart failure patients with left
ventricular systolic dysfunction, Cytokine 49 (2010) 264–268.
[17] P Fischer, D. Hilﬁker-Kleiner, Role of gp130-mediated
signalling pathways in the heart and its impact on potential
therapeutic aspects, British Journal of Pharmacology 153
(2008) 414–427.
[18] A.S. Gabriel, A. Martinsson, B. Wretlind, et al., IL-6 levels in
acute and post myocardial infarction: their relation to CRP
levels, infarction size, left ventricular systolic function, and
heart failure, European Journal of Internal Medicine 15 (2004)
523–528.
[19] B. Hudzik, J. Szkodzinski, W. Romanowski, et al., Serum
interleukin-6 concentration reﬂects the extent of
asymptomatic left ventricular dysfunction and predicts
progression to heart failure in patients with stable coronary
artery disease, Cytokine 54 (1) (2011) 266–271.
[20] T. Hamid, Y. Gu, R.V. Ortines, et al., Divergent tumour
necrosis factor receptor-related remodelling responses in
heart failure: role of nuclear factor-kappaB and
inﬂammatory activation, Circulation 119 (1) (2009) 1386–1397.
[21] M. Petretta, G.L. Condorelli, L. Spinelli, et al., Circulating
levels of cytokines and their site of production in patients
with mild to severe chronic heart failure, American Heart
Journal 140 (2000) E28.
[22] M. Rivera, R. Taléns-Visconti, R. Sirera, et al., Soluble
TNF-alpha and interleukin-6 receptors in the urine of heart
failure patients. Their clinical value and relationship with
plasma levels, European Journal of Heart Failure 6 (2004)
877–882.
[23] A. Deswal, N.J. Petersen, A.M. Feldman, et al., Cytokines and
cytokine receptors in advanced heart failure: an analysis ofthe cytokine database from the Vesnarinone trial (VEST),
Circulation 103 (2001) 2055–2059.
[24] S.M. Dunlay, S.A. Weston, M.M. Redﬁeld, et al., Tumour
Necrosis Factor Alpha (TNFα) and Mortality in Heart Failure:
a community study, Circulation 118 (2008) 625–631.
[25] S. Verma, C.H. Wang, S.H. Li, et al., A self-fulﬁlling prophecy:
C-reactive protein attenuates nitric oxide production and
inhibits angiogenesis, Circulation 106 (2002) 913–919.
[26] I.S. Anand, R. Latini, V.G. Florea, et al., C-reactive protein in
heart failure: prognostic value and the effect of valsartan,
Circulation 112 (2005) 1428–1434.
[27] M. Valko, D. Leibfritz, J. Moncol, et al., Free radicals and
antioxidants in normal physiological functions and human
disease, The International Journal of Biochemistry and Cell
Biology 39 (2007) 44–84.
[28] B.J. Thannickal, B.L. Fanburg, Reactive oxygen species in cell
signalling, American Journal of Physiology. Lung Cellular and
Molecular Physiology 279 (2000) 1005–1028.
[29] F.G. Spinale, Matrix metalloproteinases: regulation and
dysregulation in the failing heart, Circulation Research 90
(2002) 520–530.
[30] D.J. Grieve, A.M. Shah, Oxidative stress in heart failure: more
than just damage, European Heart Journal 24 (2003)
2161–2163.
[31] K.K. Griendling, D. Sorescu, M. Ushio-Fukai, NAD(P)H
oxidase; role in cardiovascular biology and disease,
Circulation Research 86 (2000) 494–501.
[32] J.K. Bendall, A.C. Cave, C. Heymes, et al., Pivotal role of
gp91phox-containing NADPH oxidase in angiotensin II-
induced cardiac hypertrophy, Circulation 105 (2002) 293–296.
[33] W.H. Tang, M.L. Brennan, K. Philip, et al., Plasma
myeloperoxidase levels in patients with chronic heart
failure, American Journal of Cardiology 98 (2006) 796–799.
[34] I. Kameda, T. Matsunaga, N. Abe, et al., Correlation of
oxidative stress with activity of matrix metalloproteinase in
patients with coronary artery disease. Possible role for left
ventricular remodelling, European Heart Journal 24 (2003)
2180–2185.
[35] M.M. Kittleson, M.E. John St, V. Bead, et al., Increased levels
of uric acid predict haemodynamic compromise in patients
with heart failure independently of B‐type natriuretic
peptide levels, Heart 93 (2007) 365–367.
[36] S.D. Anker, W. Doehner, M. Rauchhaus, et al., Uric acid and
survival in chronic heart failure: validation and application
in metabolic, functional, and hemodynamic paging,
Circulation 107 (2003) 1991–1997.
[37] A.H. Wagner, T. Kohler, U. Ruckschloss, et al., Improvement
of nitric oxide-dependent vasodilatation by HMG-CoA
reductase inhibitors through attenuation of endothelial
superoxide anion formation, Arteriosclerosis, Thrombosis
and Vascular Biology 20 (2000) 61–69.
[38] N.G. Morgenthaler, J. Struck, S. Jochberger, et al., Copeptin:
clinical use of a new biomarker, Trends in Endocrinology and
Metabolism 19 (2008) 43–49.
[39] C.L. Holmes, D.W. Landry, J.T. Granton, Science review:
Vasopressin and the cardiovascular system part 1—receptor
physiology, Critical Care 7 (2003) 427–434.
[40] G. Gimpl, F. Fahrenholz, The oxytocin receptor system:
structure, function, and regulation, Physiological Reviews 81
(2001) 629–683.
[41] A.L. García-Villalón, J.L. Garcia, N. Fernández, et al., Regional
differences in the arterial response to vasopressin: role of
endothelial nitric oxide, British Journal of Pharmacology 118
(1996) 1848–1854.
[42] J. Gutkowska, M. Jankowski, C. Lambert, Oxytocin releases
atrial natriuretic peptide by combining with oxytocin
receptors in the heart, Proceedings of the National Academy
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 4 5 – e 3 5 4 e353of Sciences of the United States of America 94 (1997)
11704–11709.
[43] T. Zenteno-Savin, I. Sada-Ovalle, G. Ceballos, et al., Effects of
arginine vasopressin in the heart are mediated by speciﬁc
intravascular endothelial receptors, European Journal of
Pharmacology 410 (2000) 15–23.
[44] Y. Xu, L. Sandirasegarane, V. Gopalakrishnan, Protein kinase
C inhibitors enhance endothelin-1 and attenuate
vasopressin and angiotensin II evoked [Ca2+]i elevation in
the rat cardiomyocyte, British Journal of Pharmacology 108
(1993) 6–8.
[45] C.L Holmes, D.W. Landry, J.T. Granton, Science review:
Vasopressin and the cardiovascular system part 2—clinical
physiology, Critical Care 8 (2004) 15–23.
[46] W.A Boyle 3rd, L.D. Segel, Attenuation of vasopressin-
mediated coronary constriction and myocardial depression
in the hypoxic heart, Circulation Research 66 (1990) 710–721.
[47] D. Stolz, M. Christ-Crain, N.G. Morgenthaler, et al., Copeptin,
C-reactive protein and procalcitonin as prognostic
biomarkers in acute exacerbation of COPD, Chest 131 (2007)
1058–1067.
[48] I. Katan, F. Fluri, N.G. Morgenthaler, et al., Copeptin: a novel,
independent prognostic marker in patients with ischaemic
stroke, Annals of Neurology 66 (2009) 799–808.
[49] P. Ošt'adal, A. Kruger, V. Zdrahalova, et al., Blood levels of
copeptin on admission predict outcomes in out-of-hospital
cardiac arrest survivors treated with therapeutic
hypothermia, Critical Care 16 (2012) R187.
[50] K. Chatterjee, Neurohormonal activation in congestive heart
failure and the role of vasopressin, The America Journal of
Cardiology 95 (2005) 8B–13B.
[51] J. Fukuzawa, T. Haneda, K. Kikuchi, Arginine vasopressin
increases the rate of protein synthesis in isolated perfused
adult rat heart via the V1 receptor, Molecular and Cellular
Biochemistry 195 (1999) 93–98.
[52] Y.H. Fan, L.Y. Zhao, Q.S. Zheng, et al., Arginine vasopressin
increases iNOS-NO system activity in cardiac ﬁbroblasts
through NF-kappaB activation and its relation with
myocardial ﬁbrosis, Life Sciences 81 (2007) 327–335.
[53] S.R. Goldsmith, The role of vasopressin in congestive heart
failure, Cleveland Clinical Journal of Medicine 73 (2006)
19–23.
[54] J.J. Preibisz, J.E. Sealey, J.H. Laragh, Plasma and platelet
vasopressin in essential hypertension and congestive heart
failure, Hypertension 5 (1983) I129–138.
[55] G. Baumann, J.F. Dingman, Distribution, blood transport, and
degradation of antidiuretic hormone in man, The Journal of
Clinical Investigation 57 (1976) 1109–1116.
[56] B. Stoiser, D. Mörtl, M. Hülsmann, et al., Copeptin, a fragment
of the vasopressin precursor, as a novel predictor of outcome
in heart failure, European Journal of Clinical Investigation 36
(2006) 771–778.
[57] S. Neuhold, M. Huelsmann, G. Strunk, et al., Comparison of
copeptin, B-type natriuretic peptide, and amino-terminal
pro-B-type natriuretic peptide in patients with chronic heart
failure: prediction of death at different stages of the dinase,
Journal of the American College of Cardiology 52 (2008)
266–272.
[58] S.Q. Khan, O.S. Dhillon, R.J. O'Brien, C-terminal
provasopressin (copeptin) as a novel and prognostic marker
in acute myocardial infarction: Leicester Acute Myocardial
Infarction Peptide (LAMP) study, Circulation 115 (2007)
2103–2110.
[59] D. Kelly, I.B. Squire, S.Q. Khan, et al., C-terminal
provasopressin (copeptin) is associated with left ventricular
dysfunction, remodeling, and clinical heart failure in
survivors of myocardial infarction, Journal of Cardiac Failure
14 (2008) 739–745.[60] S. Masson, R. Latini, E. Carbonieri, et al., The predictive value
of stable precursor fragments of vasoactive peptides in
patients with chronic heart failure: data from the GISSI-heart
failure (GISSI-HF) trial, European Journal of Heart Failure 12
(2010) 338–347.
[61] K. Kitamura, K. Kangawa, M. Kawamoto, et al.,
Adrenomedullin: novel hypotensive peptide isolated from
human pheochromocytoma, Biochemical and Biophysical
Research Communications 192 (1993) 553–560.
[62] Y. Ichiki, K. Kitamura, K. Kangawa, et al., Distribution and
characterization of immunoreactive adrenomedullin in
human tissue and plasma, FEBS Letters 338 (1994) 6–10.
[63] S. Sugo, N. Minamino, K. Kangawa, et al., Endothelial cells
actively synthesize and secrete adrenomedullin, Biochemical
and Biophysical Research Communications 201 (1994)
1160–1166.
[64] J. Roh, C.L. Chang, A. Bhalla, et al., Intermedin is a calcitonin/
calcitonin gene-related peptide family peptide acting
through the calcitonin receptor-like receptor/receptor
activity-modifying protein receptor complexes, The Journal
of Biological Chemistry 279 (2004) 7264–7274.
[65] K. Kitamura, K. Kangawa, T. Eto, Adrenomedullin and PAMP:
discovery, structures, and cardiovascular functions,
Microscopy Research and Technique 57 (2002) 3–13.
[66] T. Shimosawa, T. Fujita, Adrenomedullin and its related
peptide, Endocrine Journal 52 (2005) 1–10.
[67] L.M. McLatchie, N.J. Fraser, M.J. Main, et al., RAMPs regulate
the transport and ligand speciﬁcity of the calcitonin-
receptor-like receptor, Nature 393 (1998) 333–339.
[68] T. Ishimitsu, H. Ono, J. Minami, et al., Pathophysiologic and
therapeutic implications of adrenomedullin in
cardiovascular disorders, Pharmacology and Therapeutics
111 (2006) 909–927.
[69] I. Szokodi, P. Kinnunen, P. Tavi, et al., Evidence for cAMP-
independent mechanisms mediating the effects of
adrenomedullin, a new inotropic peptide, Circulation 97
(1998) 1062–1070.
[70] I. Nagaya, T. Satoh, T. Nishikimi, et al., Hemodynamic, renal,
and hormonal effects of adrenomedullin infusion in patients
with congestive heart failure, Circulation 101 (2000) 498–503.
[71] T. Ishimitsu, T. Nishikimi, Y. Saito, et al., Plasma levels of
adrenomedullin, a newly identiﬁed hypotensive peptide, in
patients with hypertension and renal failure, The Journal of
Clinical Investigation 94 (1994) 2158–2161.
[72] F. Pousset, F. Masson, O. Chavirovskaia, et al., Plasma
adrenomedullin, a new independent predictor of prognosis
in patients with chronic heart failure, European Heart
Journal 21 (2000) 1009–1014.
[73] I. Nagaya, T. Nishikimi, M. Uematsu, et al., Plasma
adrenomedullin as an indicator of prognosis after acute
myocardial infarction, Heart 81 (1999) 483–487.
[74] S.Q. Khan, R.J. O'Brien, J. Struck, et al., Prognostic value of
midregional pro-adrenomedullin in patients with acute
myocardial infarction: the LAMP (Leicester Acute Myocardial
Infarction Peptide) study, Journal of American College of
Cardiology 49 (2007) 1525–1532.
[75] M. Christ-Crain, N.G. Morgenthaler, J. Struck, et al., Mid-
regional pro-adrenomedullin as a prognostic marker in
sepsis: an observational study, Critical Care 9 (2005) 816–824.
[76] M. Christ-Crain, N.G. Morgenthaler, D. Stolz, et al., Pro-
adrenomedullin to predict severity and outcome in
community-acquired pneumonia, Critical Care 10 (2006) R96.
[77] K. Meeran, D. O'Shea, P.D. Upton, Circulating adrenomedullin
does not regulate systemic blood pressure but increases
plasma prolactin after intravenous infusion in humans: a
pharmacokinetic study, The Journal of Clinical
Endocrinology and Metabolism 82 (1997) 95–100.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 3 4 5 – e 3 5 4e354[78] J. Struck, C. Tao, N.G. Morgenthaler, A. Bergmann,
Identiﬁcation of an Adrenomedullin precursor fragment in
plasma of sepsis patients, Peptides 25 (2004) 1369–1372.
[79] I.T. Klip, A.A. Voors, S.D. Anker, et al., Prognostic value of
mid-regional pro-adrenomedullin in patients with heart
failure after an acute myocardial infarction, Heart 97 (2011)
892–898.
[80] S. von Haehling, G.S. Filippatos, J. Papassotiriou, et al., Mid-
regional pro-adrenomedullin as a novel predictor of
mortality in patients with chronic heart failure, European
Journal of Heart Failure 12 (2010) 484–491.
[81] A. Maisel, C. Mueller, R. Nowak, et al., Mid-region pro-
hormone markers for diagnosis and prognosis in acute
dyspnea: results from the BACH (Biomarkers in Acute Heart
Failure), Journal of the American College of Cardiology 55
(2010) 2062–2076.
[82] R.V. Shah, Q.A. Truong, H.K. Gaggin, et al., Mid-regional pro-
atrial natriuretic peptide and pro-adrenomedullin testing for
the diagnostic and prognostic evaluation of patients with
acute dyspnoea, European Heart Journal 33 (17) (2012)
2197–2205.
[83] E.O. Weinberg, M. Shimpo, G.W. De Keulenaer, et al.,
Expression and regulation of ST2, an interleukin-1 receptor
family member, in cardiomyocytes and myocardial
infarction, Circulation 106 (2002) 2961–2966.
[84] H. Iwahana, K. Yanagisawa, A. Ito-Kosaka, et al., Different
promoter usage and multiple transcription initiation sites of
the interleukin-1 receptor-related human ST2 gene in UT-7
and TM12 cells, European Journal of Biochemistry 264 (1999)
397–406.
[85] S. Sanada, D. Hakuno, L. Higgins, et al., IL-33 and ST2
comprise critical biomechanically induced and
cardioprotective signalling systém, The Journal of Clinical
Investigaion 117 (2007) 1538–1549.
[86] D. Xu, W.L. Chan, B.P. Leung, et al., Selective expression of a
stable cell surface molecule on type 2 but not type 1 helper T
cells, The Journal of Experimental Medicine 187 (1998)
787–794.
[87] J. Schmitz, A. Owyang, E. Oldham, et al., IL-33, an interleukin-
1-like cytokine that signals via the IL-1 receptor-related
protein ST2 and induces T helper type-2 associated
cytokines, Immunity 23 (2005) 479–490.
[88] S. Seki, S. Sanada, A.Y. Kudinova, et al., Interleukin-33
prevents apoptosis and improves survival after experimental
myocardial infarction through ST2 signaling, Circulation
Heart Failure 2 (2009) 684–691.
[89] E.E. Coglianese, M.G. Larson, R.S. Vasan, et al., Distribution
and clinical correlates of the interleukin receptor family
member soluble ST2 in the Framingham heart study, Clinical
Chemistry 58 (2012) 1673–1681.
[90] J.P. Januzzi, W.F Peacock, A.S. Maisel, et al., Measurement of
the interleukin family member ST2 in patients with acute
dyspnea: results from the PRIDE, Journal of the American
College of Cardiology 50 (2007) 607–613.
[91] S.U. Rehman, T. Mueller, J.L. Januzzi Jr., Characteristics of the
novel interleukin family biomarker ST2 in patients with
acute heart failure, Journal of the American College of
Cardiology 52 (2008) 1458–1465.
[92] R.V. Shah, A.A. Chen-Tournoux, M.H. Picard, et al., Serum
levels of the interleukin-1 receptor family member ST2,
cardiac structure and function , and long-term mortality in
patients with acute dyspnea, Circulation Heart Failure 2
(2009) 311–319.
[93] R.Y. Yang, G.A. Rabinovich, F.T. Liu, Galectins: structure,
function and therapeutic potential, Expert Reviews in
Molecular Medicine 10 (2008) E17.
[94] E.A. Barboni, S. Bawumia, K. Henrick, et al., Molecular
modeling and mutagenesis studies of the N-terminaldomains of galectin-3: evidence for participation with the C-
terminal carbohydrate recognition domain in
oligosaccharide binding, Glycobiology 10 (2000) 1201–1208.
[95] R.A. de Boer, L. Yu, D.J. van Veldhuisen, Galectin-3 in cardiac
remodeling and heart failure, Current Heart Failure Reports 7
(2010) 1–8.
[96] F.T. Liu, G.A. Rabinovich, Galectins as modulators of tumour
progression, Nature Reviews Cancer 5 (2005) 29–41.
[97] H. Sano, D.K. Hsu, J.R. Apgar, et al., Critical role of galectin-3
in phagocytosis by macrophages, The Journal of Clinical
Investigation 112 (2003) 389–397.
[98] M.T. Elola, C. Wolfenstein-Todel, M.F. Troncoso, et al.,
Galectins: matricellular glycan-binding proteins linking cell
adhesion, migration, and survival, Cellular and Molecular
Life Sciences 64 (2007) 1679–1700.
[99] R.C. Hughes, Secretion of the galectin family of mammalian
carbohydrate-binding family proteins, Biochimica et
Biophysica Acta 1473 (1999) 172–185.
[100] H. Kim, J. Lee, J.W. Hyun, et al., Expression and
immunohistochemical localization of galectin-3 in various
mouse tissues, Cell Biology International 31 (2007) 655–662.
[101] S.L. Friedman, Molecular regulation of hepatic ﬁbrosis, an
integrated cellular response to tissue injury, The Journal of
Biological Chemistry 275 (2000) 2247–2250.
[102] R.D. Brown, S.K. Ambler, M.D. Mitchell, et al., The cardiac
ﬁbroblast: therapeutic target in myocardial remodeling and
failure, Annual Review of Pharmacology and Toxicology 45
(2005) 657–687.
[103] N.C. Henderson, A.C. Mackinnon, S.L. Farnworth, et al.,
Galectin-3 regulates myoﬁbroblast activation and hepatic
ﬁbrosis, Proceedings of the National Academy of Sciences of
the United States of America 103 (2006) 5060–5065.
[104] Y. Nishi, H. Sano, T. Kawashima, et al., Role of galectin-3 in
human pulmonary ﬁbrosis, Allergology International 56
(2007) 57–65.
[105] L. Wang, H. Friess, Z. Zhu, et al., Galectin-1 and galectin-3 in
chronic pancreatitis, Laboratory Investigation 80 (2000)
1233–1241.
[106] U.C. Sharma, S. Pokharel, T.J. van Brakel, et al., Galectin-3
marks activated macrophages in failure-prone
hypertrophied hearts and contributes to cardiac
dysfunction, Circulation 110 (2004) 3121–3128.
[107] R.A. de Boer, A.A. Voors, P. Muntendam, et al., Galectin-3: a
novel mediator of heart failure development and
progression, European Journal of Heart Failure 11 (2009)
811–817.
[108] J.E. Ho, Ch. Liu, A. Lyass, et al., Marker of cardiac ﬁbrosis,
predicts incident heart failure in the community, Journal of
the American College of Cardiology 60 (2012) 1249–1256.
[109] D. Lok, P. van der Meer, P.B. de La Porte, et al., Galectin-3, a
novel marker of macrophage activity, predicts outcome in
patients with stable chronic heart failure, Journal of
American College of Cardiology 49 (2007) 98 A.
[110] R.R. van Kimmenade, J.L. Januzzi Jr, P.T. Ellinor, et al., Utility
of aminoterminal pro-brain natriuretic peptide, galectin-3,
and apelin for the evaluation of patients with acute heart
failure, Journal of American College of Cardiology 48 (2006)
1217–1224.
[111] H. Milting, P. Ellinghaus, M. Seewald, et al., Plasma
biomarkers of myocardial ﬁbrosis and remodeling in
terminal heart failure patients supported by mechanical
circulatory support device, The Journal of Heart and Lung
Transplantation 27 (2008) 589–596.
[112] R.A. de Boer, D.J. Lok, T. Jaarsma, et al., Predictive value of
plasma galectin-3 levels in heart failure with reduced and
preserved ejection fraction, Annals of Medicine 43 (2011)
60–68.
